Cicletanine
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
ATC code | C03BX03 (WHO) |
Pharmacokinetic data | |
Protein binding | 97.3% |
Biological half-life | 7.9 h |
Identifiers | |
| |
CAS Number | 89943-82-8 |
PubChem (CID) | 54910 |
ChemSpider | 49583 |
UNII | CHG7QC509W |
KEGG | D03487 |
ChEMBL | CHEMBL191886 |
ECHA InfoCard | 100.158.583 |
Chemical and physical data | |
Formula | C14H12ClNO2 |
Molar mass | 261.703 g/mol |
3D model (Jmol) | Interactive image |
| |
| |
(verify) |
Cicletanine is a furopyridine low-ceiling diuretic drug, usually used in the treatment of hypertension.[1] The drug is manufactured by Ipsen and marketed by Recordati (in France) under the trade name Tenstaten.
It appears to be more potent in salt-sensitive hypertension.[2]
Mechanism
It can inhibit protein kinase C.[3]
References
- ↑ Jean Sassard (1992). Genetic Hypertension. John Libbey Eurotext. ISBN 978-0-86196-313-3.
- ↑ Bagrov AY; Dmitrieva RI; Dorofeeva NA; et al. (February 2000). "Cicletanine reverses vasoconstriction induced by the endogenous sodium pump ligand, marinobufagenin, via a protein kinase C dependent mechanism". J. Hypertens. 18 (2): 209–15. doi:10.1097/00004872-200018020-00012. PMID 10694190.
- ↑ Fedorova OV, Talan MI, Agalakova NI, Droy-Lefaix MT, Lakatta EG, Bagrov AY (March 2003). "Myocardial PKC beta2 and the sensitivity of Na/K-ATPase to marinobufagenin are reduced by cicletanine in Dahl hypertension". Hypertension. 41 (3): 505–11. doi:10.1161/01.HYP.0000053446.43894.9F. PMID 12623951.
External links
This article is issued from Wikipedia - version of the 9/23/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.